David Miklos, MD, Stanford University
Articles by David Miklos, MD, Stanford University
Concluding Thoughts on the DLBCL Treatment Landscape
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Grzegorz S. Nowakowski, MD,Richard T. Maziarz, MD DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Use of CAR T-Cell Therapies in Earlier Lines of DLBCL
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.
Monoclonal Antibodies for Treatment of R/R DLBCL
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.
Real-World Data With CAR-T Therapies in R/R DLBCL
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.
Safety With CAR-T Therapies in R/R DLBCL
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.
CAR-T Therapies in R/R DLBCL
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.
CAR-T Therapy
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.
Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma
ByKami J. Maddocks, MD,Jason Westin, MD,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD,David Miklos, MD, Stanford University Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.
Front-Line Treatment of DLBCL
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.
Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease
ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.
Ongoing Issues in CAR T-Cell Therapy and Lymphoma
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
Developing CAR T-Cell Trials
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
Allogenic CAR T-Cell Therapy in Lymphoma
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
CAR T-Cell Therapy’s Future for Lymphoma
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
CAR T Cells and Lymphoma Adverse Events
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
LBCL Therapy: The Right Therapy
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
R/R NHL: Candidate Identification and Referrals
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
CAR T-Cell Therapy for Follicular Lymphoma
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
LDH and ECOG Performance Tests
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
Liso-cel Therapy in R/R Large B-Cell Lymphoma
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
The Importance of Antigen Loss in R/R Disease
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
R/R Large B-Cell Therapy in Managing Various Lymphomas
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
CAR T-Cell Therapy in Managing Various Lymphomas
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
Rationale for Further Development of CAR T-Cell therapy
ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center 
David Miklos, MD, discusses the process of developing KTE-X19 and the ZUMA-2 trial in mantle cell lymphoma.
David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.
David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.
David Miklos, MD, discusses the safety profile of KTE-X19 in mantle cell lymphoma.
Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Dr. Miklos on the Results of the ZUMA-2 Trial in MCL
Dr. Miklos on the Safety Profile of KTE-X19 in MCL
Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL
Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision